Key Highlights - Enrollment to-date of 52 patients in the ongoing Halneuron Phase 2b Trial - ATLANTA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and fatigue- related disorders, today announced financial results for the second quarter ended June 30, 2025. "With no FDA approved treatments to manage the neuropathic pain often resulting from chemotherapy treatment, we have the oppor ...